Stockreport

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

Editas Medicine, Inc.  (EDIT) 
Last editas medicine, inc. earnings: 2/26 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.editasmedicine.com
PDF Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Co [Read more]